Brain-computer interfaces

Core thesis

Invasive BCI has moved from first-in-human (Neuralink, 2024) to small but growing cohorts – roughly 26 Neuralink participants by mid-2026 – with Synchron offering a less invasive endovascular route via blood vessels and heading into the first FDA pivotal trial. The near-term value is therapeutic: restoring communication and movement for paralysed and severe-speech-loss patients, a niche of perhaps tens of thousands. The long-term vision (cognitive enhancement, memory augmentation) remains years to decades away. Three things still stand between the technology and a real market: whether electrodes hold a stable signal for years, whether payers will reimburse, and whether the surgical risk is justified for each indication.

State of the art (2026)

Invasive BCI has left the demo phase. Neuralink has implanted roughly 26 participants across its PRIME, VOICE (speech) and CONVOY (robotic-arm) studies, with sites now live in the US, UK, Canada and UAE. Synchron completed its six-patient COMMAND feasibility study on safety and, backed by a $200M Series D raised in November 2025, is moving into the pivotal trial that precedes the first FDA premarket approval of a permanent implant. Precision Neuroscience won 510(k) clearance for its 1,024-channel Layer 7 surface array in March 2025 (30-day use) and is running extended-duration studies at six centres. The unresolved questions are chronic electrode stability, reimbursement and whether non-invasive rivals close the gap.